|
|
Post by bthomas55ep on Jun 1, 2024 15:46:38 GMT -5
With the ongoing debate about the purpose of this deal, I still feel that the most obvious motivation is acquisition if Pulmatrix can demonstrate efficacy with DHE on Cricket in their upcoming phase 2 trial. The investment right now is a drop in the bucket if you are ultimately able to add another mnkd drug and delivery device to the portfolio long term. Let Pulmatrix conduct their phase 2 trials on Cricket for which they have already have an IND. Let them burn through the rest of their money all the while you prop them up a bit and now essentially own everything they have (all the while letting revenue and market cap continue to grow). Finish the acquisition in 2025/2026 when they are out of money in a stock deal (and a bigger market cap will afford less dilution), conduct the phase 3 DHE trials towards another approved product on Mannkind Technology, and as a byproduct,own another device technology in iSphere along with the additional pipeline of drugs it currently suggests. If I were CEO, this is certainly the way I'd be thinking about a low impact way to grow my business while still trying to be become a big boy. While $300 million in cash sounds good, with nearly as much debt coming due in the not too distant feature, Mannkind is still far from being out of the woods. Of course I know nothing, but swinging to get another ball out of the park is still a necessary reality for this business. For $10M bucks annually? They could drop that much on a big trade show. I think this would be a worthwhile strategy with acceptable levels of distraction. My $.02. GLTA What would possible be the benefit of that for MNKD. Saves Pulmatrix some money in designing and testing, but it's just a plastic whistle. It takes a lot of money though to design/test/validate anything in medical space. But I'd guess zero chance any company would actually pay money to license a simple plastic inhaler from MNKD. Technosphere arguably has some value, though I certainly think as shareholders we way overvalued that in the past. But a plastic whistle inhaler... that's not going to be a revenue source for MNKD even if Pulm uses it for an FDA approved drug. That's a lot of speculation on future deals. It certainly doesn't smell like that to me. I won't attempt to counter your intuition (or rather your sense of smell), however, an FDA approved drug for treating acute migraines using Cricket (if it has proven more effective than iSphere) wholly owned by Mannkind adding to their existing portfolio of drugs has a lot of potential value. I agree, having Pulmatrix license the Cricket as the end game isn't a strategy and that's not what I was implying. Thx |
|
|
|
Post by ktim on Jun 1, 2024 16:00:23 GMT -5
What would possible be the benefit of that for MNKD. Saves Pulmatrix some money in designing and testing, but it's just a plastic whistle. It takes a lot of money though to design/test/validate anything in medical space. But I'd guess zero chance any company would actually pay money to license a simple plastic inhaler from MNKD. Technosphere arguably has some value, though I certainly think as shareholders we way overvalued that in the past. But a plastic whistle inhaler... that's not going to be a revenue source for MNKD even if Pulm uses it for an FDA approved drug. That's a lot of speculation on future deals. It certainly doesn't smell like that to me. I won't attempt to counter your intuition (or rather your sense of smell), however, an FDA approved drug for treating acute migraines using Cricket (if it has proven more effective than iSphere) wholly owned by Mannkind adding to their existing portfolio of drugs has a lot of potential value. I agree, having Pulmatrix license the Cricket as the end game isn't a strategy and that's not what I was implying. Thx I did misinterpret the statement I'd highlighted. If MNKD really wanted their Migraine treatment I think the deal would have been structured differently, such as MNKD providing some equity based cash infusion with warrants and/or a less absolute license for cricket. There is nothing here that indicates they have their eye on the migraine product. It's not impossible what you theorize... just doesn't seem like the patterns I'm familiar with in business. |
|
